

RECEIVED
CENTRAL FAX CENTER

004/066

MAY 21 2008

PTO/SB/08b (01-08)

Approved for use through 05/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/632,187
Filing Date	July 30, 2003
First Named Inventor	Jürgen Engel et al.
Art Unit	1614
Examiner Name	Shirley V. Gembeh

Attorney Docket Number

103632-477-NP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PRINCIPE et al., Synergistic cytotoxic effect of aza-alkylphospholipids in association with chemotherapeutic drugs, J. Lipid Mediators Cell Signalling, 10, 1994, pp. 171-173	
		PRINCIPE et al., Evaluation of combinations of antineoplastic ether phospholipids and chemotherapeutic drugs, Anti-Cancer Drugs, 3, 1992, pp. 577-587	
		RUITER et al., Alkyl-Lysophospholipids As Anticancer Agents and Enhancers of Radiation-Induced Apoptosis, Int. J. Radiation Oncology Biol. Phys., 49(2), 2001, pp. 415-419	
		MALY et al., Interference of new alkylphospholipid analogues with mitogenic signal transduction, Anti-Cancer Drug Design, 10, 1995, pp. 411-425	
		LOHMEYER et al., Antitumor ether lipids and alkylphosphocholines, Drugs of the Future, 19(11), 1994, pp. 1021-1037	
		HILGARD et al, D-21266, a New Heterocyclic Alkylphospholipid with Antitumour Activity, European Journal of Cancer, 33(3), 1997, pp. 442-446	
		Australian Search Report	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

#4724859